Treace Medical Concepts, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Sean F. Scanlan, Chief Innovation Officer of Treace Medical Concepts, Inc., reported a transaction in 9,814 shares of common stock on August 9, 2026.
NASDAQ
Mark Hair, Chief Financial Officer of Treace Medical Concepts, Inc., reported a transaction in 37,102 shares of common stock on August 9, 2026.
NASDAQ
Scot Michael Elder, Chief Legl & Comp Off, CorpSec of Treace Medical Concepts, Inc., reported a transaction in 16,253 shares of common stock on August 9, 2026.
NASDAQ
CEO John Treace filed an amendment to correct administrative errors regarding the volume of shares purchased on June 10 and 11, 2026.
NASDAQ
CEO John Treace purchased 52,317 shares of Treace Medical Concepts, Inc. across two days of open market transactions.
NASDAQ
John T. Treace, CEO of Treace Medical Concepts, Inc. (TMCI), acquired 50,000 shares of common stock on June 1, 2026, at an average price of $3.5583 per share.
NASDAQ
CEO John Treace purchased 115,520 shares of Treace Medical Concepts, Inc. across three days in May 2026.
NASDAQ
Treace Medical Concepts director John Bakewell was granted 30,000 restricted stock units as part of an equity compensation award.
NASDAQ
Treace Medical Concepts director Jane E. Kiernan was granted 30,000 restricted stock units as part of annual compensation.
NASDAQ
Director Lance A. Berry was granted 30,000 restricted stock units (RSUs) by Treace Medical Concepts, Inc. on May 19, 2026.
NASDAQ
Director Deepti Jain was granted 30,000 restricted stock units by Treace Medical Concepts, Inc. on May 19, 2026.
NASDAQ
Treace Medical Concepts director Lawrence Hamilton was granted 30,000 restricted stock units as part of annual compensation.
NASDAQ
Treace Medical Concepts, Inc. director Betsy Hanna was granted 30,000 restricted stock units as part of annual compensation.
NASDAQ
CEO John Treace purchased 153,763 shares of Treace Medical Concepts, Inc. (TMCI) across three days in May 2026.
NASDAQ
Chief Financial Officer Mark Hair disposed of 11,547 shares of Treace Medical Concepts to satisfy tax withholding requirements.
NASDAQ
Treace Medical Concepts, Inc. reports that Chief Financial Officer Mark Hair acquired 100,000 performance stock units on April 1, 2026, with vesting scheduled through 2029.
NASDAQ
Scot Elder, Chief Legal and Compliance Officer of Treace Medical Concepts, Inc., disposed of common stock to cover tax withholding obligations.
NASDAQ
Treace Medical Concepts' Chief Innovation Officer, Sean Scanlan, reported the disposition of 1,797 shares of common stock over two days, primarily for tax withholding purposes.
NASDAQ
Treace Medical Concepts CEO John T. Treace reported the disposition of 7,083 common shares for tax withholding purposes.
NASDAQ
Treace Medical Concepts CFO Mark Hair disposed of common stock to cover tax withholding obligations related to restricted stock unit vesting.
NASDAQ
Treace Medical Concepts' Chief Innovation Officer, Sean F. Scanlan, acquired 16,875 shares of common stock through a stock option exercise.
NASDAQ
Treace Medical Concepts' Chief Commercial Officer, Gaetano Guglielmino, was granted 150,000 restricted stock units, vesting over four years.
NASDAQ
Scot Elder, Chief Legal & Compliance Officer of Treace Medical Concepts, received a grant of 262,500 restricted stock units and disposed of shares for tax purposes.
NASDAQ
Treace Medical Concepts CFO Mark Hair reported the acquisition of 375,000 restricted stock units and the disposition of 17,037 shares for tax purposes.
NASDAQ
Treace Medical Concepts' Chief Innovation Officer, Sean F. Scanlan, increased his beneficial ownership through an option exercise and a significant restricted stock unit grant.
NASDAQ
Treace Medical Concepts CEO John Treace acquired 250,000 restricted stock units and disposed of 14,254 shares for tax purposes, increasing his direct beneficial ownership.
NASDAQ
Treace Medical Concepts CFO Mark Hair reported the disposition of 8,719 common shares on January 10, 2026, to cover tax withholding obligations, retaining 510,245 shares.
NASDAQ
Treace Medical Concepts' Chief Legal Officer Scot Elder disposed of 4,544 common shares to cover tax withholding obligations.
NASDAQ
Treace Medical Concepts CEO John Treace reported the disposition of 13,219 shares of common stock for tax withholding purposes.
NASDAQ
Treace Medical Concepts' Chief Commercial Officer, Guy Guglielmino, reported the disposition of 22,099 shares of common stock to cover tax liabilities.